Catalyst Wire Dossier Catalyst Wire Dossier

CD19/CD22 dual-targeting fourth-generation CAR T cells

CAR T cells targeting CD19 and CD22 · Essen Biotech
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19/CD22 dual-targeting fourth-generation CAR T cells, covering 2025-08-06 to 2025-08-06. Get the full timeline:

Most recent: Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]

See pricing